Regeneron Pharmaceuticals, Inc. (REGN) Q3 2021 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.69%

Regeneron's strong EPS performance indicates robust profitability, but the stock's slight decline of 0.69% suggests that investors may have been expecting more comprehensive guidance or revenue details. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$15.37	N/A	+56.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings per share results, highlighting the strength of their product pipeline. However, they did not provide specific future guidance.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.69%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.69%

Key numbers

Management commentary